Dimensional Fund Advisors LP boosted its position in Zoetis Inc. (NYSE:ZTS – Free Report) by 2.2% in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,610,380 shares of the company’s stock after purchasing an additional 34,235 shares during the period. Dimensional Fund Advisors LP owned about 0.35% of Zoetis worth $277,326,000 as of its most recent SEC filing.
Several other hedge funds and other institutional investors have also recently bought and sold shares of the company. Evermay Wealth Management LLC grew its stake in Zoetis by 439.3% in the 1st quarter. Evermay Wealth Management LLC now owns 151 shares of the company’s stock valued at $25,000 after acquiring an additional 123 shares during the last quarter. Nelson Van Denburg & Campbell Wealth Management Group LLC increased its position in Zoetis by 430.8% during the 1st quarter. Nelson Van Denburg & Campbell Wealth Management Group LLC now owns 138 shares of the company’s stock worth $26,000 after purchasing an additional 112 shares in the last quarter. Worth Asset Management LLC acquired a new position in Zoetis in the 1st quarter valued at about $26,000. Pacifica Partners Inc. lifted its holdings in Zoetis by 76.9% in the 2nd quarter. Pacifica Partners Inc. now owns 161 shares of the company’s stock valued at $27,000 after purchasing an additional 70 shares in the last quarter. Finally, Altshuler Shaham Ltd acquired a new stake in shares of Zoetis during the 2nd quarter worth about $29,000. 89.47% of the stock is owned by institutional investors and hedge funds.
Zoetis Stock Performance
Shares of ZTS opened at $174.62 on Thursday. The firm has a market cap of $80.17 billion, a price-to-earnings ratio of 35.49, a PEG ratio of 2.72 and a beta of 0.83. The company has a quick ratio of 2.16, a current ratio of 3.87 and a debt-to-equity ratio of 1.29. The business’s 50 day moving average is $172.30 and its two-hundred day moving average is $175.70. Zoetis Inc. has a 52-week low of $140.76 and a 52-week high of $194.99.
Zoetis Announces Dividend
Analysts Set New Price Targets
A number of brokerages recently issued reports on ZTS. StockNews.com lowered shares of Zoetis from a “strong-buy” rating to a “buy” rating in a research report on Sunday, October 8th. The Goldman Sachs Group boosted their target price on Zoetis from $204.00 to $213.00 and gave the stock a “buy” rating in a report on Wednesday, August 9th. HSBC began coverage on shares of Zoetis in a report on Wednesday, September 6th. They issued a “buy” rating and a $230.00 price target on the stock. Argus increased their price objective on shares of Zoetis from $190.00 to $201.00 in a research report on Tuesday, September 19th. Finally, Piper Sandler lifted their target price on shares of Zoetis from $210.00 to $215.00 and gave the company an “overweight” rating in a report on Monday, November 6th. Seven analysts have rated the stock with a buy rating, According to MarketBeat.com, the company currently has a consensus rating of “Buy” and an average price target of $216.29.
Insider Buying and Selling at Zoetis
In other news, EVP Roxanne Lagano sold 923 shares of the business’s stock in a transaction dated Friday, September 1st. The shares were sold at an average price of $192.97, for a total value of $178,111.31. Following the completion of the sale, the executive vice president now owns 25,434 shares of the company’s stock, valued at approximately $4,907,998.98. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In other news, EVP Roxanne Lagano sold 923 shares of Zoetis stock in a transaction that occurred on Friday, September 1st. The stock was sold at an average price of $192.97, for a total value of $178,111.31. Following the completion of the transaction, the executive vice president now owns 25,434 shares in the company, valued at approximately $4,907,998.98. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, EVP Heidi C. Chen sold 9,905 shares of the firm’s stock in a transaction on Friday, September 15th. The stock was sold at an average price of $180.15, for a total value of $1,784,385.75. Following the transaction, the executive vice president now owns 27,478 shares in the company, valued at $4,950,161.70. The disclosure for this sale can be found here. Insiders have sold 25,674 shares of company stock worth $4,627,465 in the last ninety days. 0.15% of the stock is owned by insiders.
Zoetis Company Profile
Zoetis Inc discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.
- Five stocks we like better than Zoetis
- How to Calculate Return on Investment (ROI)
- Buffett’s latest portfolio additions, trims, and cuts in Q3
- Industrial Products Stocks Investing
- 5 reasons TJX Companies will hit new highs in 2024
- How to Invest in Pharmaceutical Companies
- Game-changing news for Ambarella puts the market in reversal
Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.